Conjunctivitis in dupilumab clinical trials

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinlade, B., Guttman‐Yassky, E., de Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850316/
https://www.ncbi.nlm.nih.gov/pubmed/30851191
http://dx.doi.org/10.1111/bjd.17869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850316/
https://www.ncbi.nlm.nih.gov/pubmed/30851191
http://dx.doi.org/10.1111/bjd.17869

Ejemplares similares